It may sound harsh, but drug candidates that are bound to be poor performers should be identified sooner rather than later—and ruthlessly eliminated from development. Granted, early in development, ...

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS ...

The advent of sophisticated cellular imaging techniques, combined with technological advances in automation and data collection and interpretation, has provided the basis for the development of ...

Creative Bioarray is excited to announce the launch of its comprehensive Drug Metabolism and Pharmacokinetics (DMPK) Services which designed to streamline drug development by providing critical ...

High-throughput screening (HTS) is crucial to generate hits and leads in drug discovery efforts. Most high-throughput biochemical assays are based on optical detection or radioactivity with high ...

"We provide reliable and cost-effective HT-ADME assays, ensuring superior quality and consistent results," said Hannah Cole, Marketing Director at Creative Bioarray. "Our high-throughput ADME ...

The in vitro assays from CN-Bio are effective in predicting clinical outcomes. High-functioning, metabolically competent human single- and multi-organ models are used in studies on drug metabolism, ...

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of ...

Research and Markets has announced the addition of the "ADME-Toxicology Testing - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for ...